Aureum’s ground-breaking Point of Care diagnostics platform delivers unparalleled performance across a wide range of critical point of care applications. Our novel electrochemical technology enables the rapid, sensitive, accurate and cost-effective measurement of metabolites, proteins and nucleic acid targets. Aureum delivers this capability in an easy to use “sample to result” format. In the last 5 years and through > £1.5 million in competitively won grants and research studentships, Professor Corrigan and his team have been working on the development of novel biosensor technologies for a range of diseases. One area of strong interest has been Covid-19, where through a Chief Scientist Office Scotland Covid Rapid Response Project, the team were able to develop several novel biosensor strategies for SARS-CoV-2. Aureum takes its initial inspiration from these developments.